Resultados: Caso Estudio de las Heparinas
“The incremental cost-effectiveness of inpatient low-molecular-weight heparin treatment was $7820 per QALY gained”
“Treatment with low-molecular-weight heparin was cost saving when as few as 8% of patients were treated at home”